News & Updates

Prior faecal haemoglobin concentrations can help predict risk of future CRC, advanced neoplasia

Prior faecal haemoglobin (F-Hb) concentrations are prognostic of the risk of developing colorectal cancer (CRC) or advanced neoplasia (AN), according to a study. When added to age and sex, prior F-Hb concentrations can accurately identify individuals at risk of the said diseases.

Tisagenlecleucel cost-effective for young adults with relapsed acute lymphoblastic leukaemia

For young adults with relapsed/refractory acute lymphoblastic leukaemia (R/R ALL) who had failed at least two prior lines of therapies, tisagenlecleucel appears to be an inexpensive treatment option, according to a recent Singapore study.

Novel cellular therapy produces impressive responses in heavily pretreated CD30-positive lymphoma

A novel cellular therapy that links the bispecific antibody AFM13 with cord blood–derived natural killer cells (AFM13-NK), when used at recommended phase II dose (RP2D), produces a 100 percent overall response rate (ORR) in patients with refractory or relapsed CD30-positive Hodgkin or non-Hodgkin lymphomas (HL/NHL), according to results of the NCT04074746 trial presented at American Association for Cancer Research (AACR) 2022.

Denosumab: A critical aspect of metastatic prostate cancer treatment

Men with metastatic prostate cancer (mPC) have an elevated risk of skeletal complications either due to bone metastases (skeletal-related events [SREs]), or from osteoporosis induced by androgen deprivation therapy (ADT). Two key opinion leaders recently shared their perspectives on bone complications in mPC as well as the use of bone-targeted agents (BTAs) such as denosumab (Xgeva) to reduce the risk of bone complications.

Professor Bertrand Tombal

Professor of Urology

Cliniques universitaires Saint-Luc & Université catholique de Louvain

Brussels, Belgium

Associate Professor Edmund Chiong

Head, Department of Urology

National University Hospital, Singapore

Polygenic risk scores for hepatic fat, NAFLD pinpoint Asians at risk of HCC

Both the polygenic risk score (PRS) for hepatic fat (HFC-PRS) derived from non-Asians and the novel PRS for nonalcoholic fatty liver disease (NAFLD) derived from East Asians can predict the incidence of hepatocellular carcinoma (HCC) in Singaporeans, as shown in a study.

Stem cell–like epigenetic signature predicts resistance to CD19 CAR T-cell therapy in ALL

A stem cell–like epigenetic signature is identified in pretreatment samples from young patients with acute lymphoblastic leukaemia (ALL) who are resistant to CD19 chimeric antigen receptor (CAR) T-cell therapy, with potential utility for refining patient selection for appropriate treatment.